These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1347103)

  • 1. Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100.
    Illingworth DR; Vakar F; Mahley RW; Weisgraber KH
    Lancet; 1992 Mar; 339(8793):598-600. PubMed ID: 1347103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypocholesterolemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100.
    Schmidt EB; Illingworth DR; Bacon S; Mahley RW; Weisgraber KH
    Atherosclerosis; 1993 Jan; 98(2):213-7. PubMed ID: 8457260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects.
    Raal FJ; Pilcher G; Rubinsztein DC; Lingenhel A; Utermann G
    Atherosclerosis; 1997 Feb; 129(1):97-102. PubMed ID: 9069523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypolipidemic effects of nicotinic acid in patients with familial defective apolipoprotein B-100.
    Schmidt EB; Illingworth DR; Bacon S; Russell SJ; Thatcher SR; Mahley RW; Weisgraber KH
    Metabolism; 1993 Feb; 42(2):137-9. PubMed ID: 8474308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial defective apolipoprotein B-100 (R3500Q) in Northern Ireland.
    McClean E; Graham CA; Ward AJ; Young IS; Martin S; Nicholls DP
    Br J Biomed Sci; 1999; 56(4):258-62. PubMed ID: 10795369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial defective apolipoprotein B-100 (FDB): effect of simvastatin therapy on LDL-receptor binding.
    Mamotte CD; Sturm M; Foo JI; van Bockxmeer FM; Taylor RR
    Atherosclerosis; 1996 Aug; 125(1):103-10. PubMed ID: 8831932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.
    Ojala JP; Helve E; Ehnholm C; Aalto-Setälä K; Kontula KK; Tikkanen MJ
    J Intern Med; 1991 Nov; 230(5):397-405. PubMed ID: 1940775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial defective apolipoprotein B-100: a lesson from homozygous and heterozygous patients.
    Ceska R; Vrablík M; Horínek A
    Physiol Res; 2000; 49 Suppl 1():S125-30. PubMed ID: 10984082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia.
    Myant NB
    Atherosclerosis; 1993 Dec; 104(1-2):1-18. PubMed ID: 8141833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The affinity of low-density lipoproteins and of very-low-density lipoprotein remnants for the low-density lipoprotein receptor in homozygous familial defective apolipoprotein B-100.
    Gallagher JJ; Myant NB
    Atherosclerosis; 1995 Jun; 115(2):263-72. PubMed ID: 7661885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of defective binding of low density lipoprotein by the U937 proliferation assay in German patients with familial defective apolipoprotein B-100.
    Schewe CK; Schuster H; Hailer S; Wolfram G; Keller C; Zöllner N
    Eur J Clin Invest; 1994 Jan; 24(1):36-41. PubMed ID: 8187806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial ligand-defective apolipoprotein B-100: detection, biochemical features and haplotype analysis of the R3531C mutation in the UK.
    Wenham PR; Henderson BG; Penney MD; Ashby JP; Rae PW; Walker SW
    Atherosclerosis; 1997 Mar; 129(2):185-92. PubMed ID: 9105560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between lovastatin and cholestyramine in the treatment of moderate to severe primary hypercholesterolaemia.
    Ebeling T; Turtola H; Voutilainen E; Uusitupa M; Pyörälä K; Reijonen T
    Ann Med; 1992 Apr; 24(2):121-7. PubMed ID: 1610539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lovastatin therapy in heterozygous familial hypercholesterolaemic patients: effect on blood rheology and fibrinogen levels.
    Beigel Y; Fuchs J; Snir M; Lurie Y; Green P; Djaldetti M
    J Intern Med; 1991 Jul; 230(1):23-7. PubMed ID: 2066708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial defective apolipoprotein B-100.
    Hansen PS
    Dan Med Bull; 1998 Sep; 45(4):370-82. PubMed ID: 9777289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial defective apo B-100, characterization of an Italian family.
    Corsini A; McCarthy BJ; Granata A; Soria LF; Fantappiè S; Bernini ; Romano C; Romano L; Fumagalli R; Catapano AL
    Eur J Clin Invest; 1991 Aug; 21(4):389-97. PubMed ID: 1936106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a heterozygous compound individual with familial hypercholesterolemia and familial defective apolipoprotein B-100.
    Rauh G; Schuster H; Fischer J; Keller C; Wolfram G; Zöllner N
    Klin Wochenschr; 1991 May; 69(7):320-4. PubMed ID: 2067318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial defective apolipoprotein B100: clinical characteristics of 54 cases.
    Rauh G; Keller C; Kormann B; Spengel F; Schuster H; Wolfram G; Zöllner N
    Atherosclerosis; 1992 Feb; 92(2-3):233-41. PubMed ID: 1632851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene?
    Leren TP; Hjermann I
    Eur J Clin Invest; 1995 Dec; 25(12):967-73. PubMed ID: 8719939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of familial defective apolipoprotein B-100 in Switzerland.
    Miserez AR; Laager R; Chiodetti N; Keller U
    J Lipid Res; 1994 Apr; 35(4):574-83. PubMed ID: 8006512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.